Guidelines | Diffuse Large B-Cell Lymphoma Guideline Updates 2023

Epcoritamab has been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for B-cell Lymphomas in the third- or later-line setting for the treatment of patients with diffuse large B-cell lymphoma.

In his closing thoughts, Dr Gordon discusses navigation of treatment resistance in DLBCL management.

The impact of collaborative care in DLBCL treatment is explored by a medical expert.